In January 2016 the Medical Technologies Evaluation Programme commenced the review of this guidance, to register as a stakeholder please contact us at firstname.lastname@example.org.
NICE has developed medical technology guidance on the CardioQ-ODM.
NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
NICE has said that the CardioQ-ODM oesophageal doppler monitor can be used in people who are having major surgery or high-risk surgery. It can also be used in people having surgery who would otherwise be monitored with a more invasive method. Hospital teams may want to use the CardioQ-ODM oesophageal doppler monitor because the evidence shows that it reduces the use of central venous catheters, complications after surgery and the length of stay in hospital without increasing the need for readmission to hospital or repeat surgery.
The guidance was amended in May 2011 to clarify that the study by Gan et al. (2002) included patients having general surgery.